A. Lutckii
5 Papers
A. Lutckii is an academic researcher. The author has contributed to research in topics: Internal medicine & Placebo. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Totally drug-resistant tuberculosis and adjunct therapies.
Shreemanta Parida,Rebecca Axelsson-Robertson,Rebecca Axelsson-Robertson,Martin Rao,Nalini Singh,Iqbal Master,A. Lutckii,S. Keshavjee,Jan Andersson,Alimuddin Zumla,Markus Maeurer,Markus Maeurer +11 more
TL;DR: Longer perspectives of drug resistance in TB and potential adjunct treatment options are reviewed to achieve better clinical outcomes in combination with standard chemotherapy.
167
Pos0649 efficacy and safety of levilimab in combination with methotrexate in patients with active rheumatoid arthritis: 1-year results of phase iii, double-blind, placebo-controlled, randomized trial
V. Mazurov,M. Korolev,Andrey Pristrom,A. Kundzer,N. Soroka,Aleksander Kastanayan,Tatyana Povarova,T. Plaksina,O. V. Antipova,Diana Kretchikova,Svetlana A Smakotina,Oksana Tciupa,Ekaterina Puntus,T Raskina,L.N. Shilova,T. Kropotina,O. Nesmeyanova,T. Popova,Irina Vinogradova,I. Linkova,A. Plotnikova,P. Pukhtinskaia,A V Zinkina-Orikhan,A. Eremeeva,A. Lutckii +24 more
TL;DR: 1-year efficacy and safety data of the open-label period of the SOLAR study of levilimab in combination with methotrexate in subjects with MTX resistant active RA is presented.
Levilimab clinical efficacy for interleukin-6 receptor inhibition in COVID-19 and its potential for treating cytokine release syndrome of other aetiologies
Nikita V. Lomakin,B. A. Bakirov,Gaziyav H. Musaev,Vladimir V. Popov,Elena A Smolyarchuk,Yu N Lin'kova,D. Bogdan,A. Eremeeva,P. Pukhtinskaia,M.A. Morozova,A V Zinkina-Orikhan,A. Lutckii +11 more
TL;DR: In this paper , the authors investigated the association of COVID-19 severity and levilimab effectiveness with interleukin-6 (IL-6) levels and explored the potential for using leiselimab in other conditions accompanied by cytokine release syndrome.
The efficacy and safety of divozilimab in patient with systemic sclerosis: 48-week results of the randomized double-blind placebo-controlled phase III clinical study LIBERIUS
L. P. Ananyeva,M. Starovoytova,I. Z. Gaydukova,G. V. Lukina,E. Zonova,L. V. Eliseeva,G. Fatkhullina,Diana Abdulganieva,Diana G Krechikova,T. Kropotina,O. Nesmeyanova,I. B. Vinogradova,Elena Zhugrova,L. V. Ivanova,N. Nikulenkova,O. R. Ziganshin,T. Plaksina,M. V. Zlobin,Yu. Yu. Grabovetskaya,N. F. Soroka,O. B. Ershova,T. Povarova,O.N. Anoshenkova,A. Lutckii,A V Zinkina-Orikhan,Yu N Lin'kova,E. A. Fokina,A. A. Porozova,P. Pukhtinskaia,A. Eremeeva +29 more
- 01 May 2025
Efficacy and safety of levilimab in combination with methotrexate in patients with active rheumatoid arthritis: 56-week results of phase III randomized double-blind placebo-controlled trial SOLAR
V. Mazurov,A M Lila,Maxim Aleksandrovich Korolev,A. Prystrom,A. Kundzer,N. Soroka,Aleksander Kastanayan,Tatyana Povarova,T. Plaksina,O. V. Antipova,Diana G Krechikova,Svetlana A Smakotina,Oksana Tciupa,E. V. Puntus,T. A. Raskina,L.N. Shilova,T. Kropotina,O. Nesmeyanova,T. Popova,I. B. Vinogradova,E. Dokukina,A. Plotnikova,P. Pukhtinskaia,A V Zinkina-Orikhan,Yu N Lin'kova,A. Eremeeva,A. Lutckii,E. Nasonov +27 more
TL;DR: In this article , the authors evaluated the efficacy and safety of levilimab in combination with methotrexate (MTX) in subjects with MTX resistant active rheumatoid arthritis.